Novel small molecule therapeutics targeting RAS and PI3Kα malignancies
搜索文档
BBOT to Participate in Upcoming September Investor Healthcare Conferences
Globenewswire· 2025-08-20 20:00
Links for live webcasts and replays, if available, will be available in the on the "Investors" page of the BBOT website. Replays will be available on the website for at least 90 days following the event. SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS- pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in S ...
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
Globenewswire· 2025-08-06 19:33
交易概况 - Helix Acquisition Corp II（HLXB）与BridgeBio Oncology Therapeutics（BBOT）宣布业务合并，Helix信托账户保留约1.2亿美元资金，占信托现金总额的60%以上[1] - 交易预计筹集总额约3.82亿美元，包括Helix信托账户的1.2亿美元和由Cormorant Asset Management领投的2.61亿美元私募配售（PIPE）[2] - 该交易创下自2022年以来生物科技领域SPAC合并的最低赎回率纪录[7] 公司背景 - Helix Acquisition Corp II（HLXB）是一家特殊目的收购公司（SPAC），成立于2024年2月，首次公开募股筹集1.84亿美元，总部位于波士顿[4] - BridgeBio Oncology Therapeutics（BBOT）是一家临床阶段生物制药公司，专注于开发针对RAS和PI3Kα恶性肿瘤的新型小分子疗法，最初为BridgeBio Pharma（BBIO）的子公司[5] 交易进展 - 双方计划在满足或豁免交割条件后迅速完成业务合并[3] - 合并后的公司将获得来自信托账户的1.2亿美元和PIPE融资的2.61亿美元资金[7]